Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Depreciation & Amortization (CF) (2017 - 2025)

Crinetics Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 9 years, most recently at $994000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $994000.0 for Q4 2025, up 26.14% from a year ago — trailing twelve months through Dec 2025 was $3.9 million (up 39.68% YoY), and the annual figure for FY2025 was $3.9 million, up 39.68%.
  • Depreciation & Amortization (CF) for Q4 2025 was $994000.0 at Crinetics Pharmaceuticals, down from $1.0 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for CRNX hit a ceiling of $1.0 million in Q3 2025 and a floor of $215000.0 in Q2 2022.
  • Median Depreciation & Amortization (CF) over the past 5 years was $280000.0 (2022), compared with a mean of $483900.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): fell 6.52% in 2022 and later surged 200.76% in 2024.
  • Crinetics Pharmaceuticals' Depreciation & Amortization (CF) stood at $235000.0 in 2021, then increased by 19.15% to $280000.0 in 2022, then dropped by 6.43% to $262000.0 in 2023, then surged by 200.76% to $788000.0 in 2024, then rose by 26.14% to $994000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $994000.0 (Q4 2025), $1.0 million (Q3 2025), and $959000.0 (Q2 2025) per Business Quant data.